Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: A pilot study

Blood Pressure

Volumn 23, Issue 6, 2014, Pages 330-338

  De Ciuceis, Carolina ^a   Flati, Vincenzo ^b   Rossini, Claudia ^a   Rufo, Anna ^b   Porteri, Enzo ^a   Di Gregorio, Jacopo ^b   Petroboni, Beatrice ^a   La Boria, Elisa ^a   Donini, Carlotta ^a   Pasini, Evasio ^c   Rosei, Enrico Agabiti ^a   Rizzoni, Damiano ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c IRCCS   (Italy)

Author keywords

Enalapril hydrochlorothiazide; GLUT 4; Insulin lymphocites; Insulin signalling; Lercanidipine; Monocytes; MTOR; Nifedipine; Telmisartan

Indexed keywords

ADENYLATE KINASE; C REACTIVE PROTEIN; ENALAPRIL; GLUCOSE TRANSPORTER 4; HYDROCHLOROTHIAZIDE; INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; LERCANIDIPINE; MACROPHAGE CHEMOTACTIC FACTOR; MALONALDEHYDE; MAMMALIAN TARGET OF RAPAMYCIN; NIFEDIPINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; S6 KINASE; TELMISARTAN; VASCULAR CELL ADHESION MOLECULE 1; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION; TARGET OF RAPAMYCIN KINASE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; LYMPHOCYTE; MALE; MONOCYTE; MONONUCLEAR CELL; MONOTHERAPY; OXIDATIVE STRESS; PILOT STUDY; POLYPHARMACY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; AGED; DRUG COMBINATION; DRUG EFFECTS; HYPERTENSION; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG COMBINATIONS; ENALAPRIL; FEMALE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPERTENSION; INSULIN; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NIFEDIPINE; PILOT PROJECTS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84910616202     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2014.901021     Document Type: Article

References (35)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-1607.
2. Reaven GM. Insulin resistance, hyperinsulinemia and hypertriglyceridemia in the etiology and the clinical course of hypertension. Am J Med. 1991; 90: 7S-12S.
3. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow: Apossible link between insulin resistance and blood pressure. Hypertension. 1993; 21: 129-135.
4. Bhanot S, McNeill JH. Insulin and hypertension: Acausal relationship? Cardiovasc Res. 1996; 31: 212-221.
5. Modan M, Halkin H, Almog S, Lusky A, Eskol A, Shefi M. Hyperinsulinemia. Alink between hypertension, obesity, and glucose intolerance. J Clin Invest. 1985; 75: 809-817.
6. Capaldo B, Lembo G, Napoli R, Rendina V, Albano G, Saccà L. Skeletal muscle is aprimary site of insulin resistance in essential hypertension. Metab Clin Exp. 1991; 40: 1320-1322.
7. Natali N, Santoro D, Palombo C, Cerri M, Ghione S, Ferrannini E. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension. 1991; 17: 170-178.
8. Pasini E, Flati V, Paiardi S, Rizzoni D, Porteri E, Aquilani R, et al. Intracellular molecular effects of insulin resistance in patients with metabolic syndrome. Cardiovasc Diabetol. 2010; 9: 46.
9. Brown EJ, Schreiber SI. Asignalling pathway to translational control. Cell. 1996; 86: 517-520.
10. Flati V, Pasini E, D'Antona G, Speca S, Toniato E, Martinotti S. Intracellular mechanisms of metabolism regulation: The role of signalling via the mTOR pathway and other routes. Am J Cardiol. 2008; 101: 16E - 21E.
11. Ponticelli C. Denovo thrombotic microangiopathy. Anunderrated complication of renal transplantation. Clinical Nephrology. 2007; 67: 335-340.
12. Ponticelli C, Banfi G. Trombotic microangiopathy after kidney transplantation. Transpl Intern. 2006; 19: 789-794.
13. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: Anetwork meta-analysis. Lancet. 2007; 369: 201-207.
14. Munoz MC, Argentino DP, Dominaci FP, Turyn D, Toblli JE. Irbesartan restores the in-vivo insulin signalling pathway leading to Akt activation in obese Zucker rats. J Hypertens. 2006; 24: 1607-1617.
15. Rizzoni D, Pasini E, Flati V, Rodella LF, Paiardi S, Assanelli D, et al. Angiotensin receptor blockers improve insulin signalling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. J Hypertens. 2008; 26: 1595-1601.
16. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al.; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31: 1281-1357.
17. De Ciuceis C, Porteri E, Rizzoni D, Corbellini C, La Boria E, Boari GE, et al. Effects of weight loss on structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension. 2011; 58: 29-36.
18. Flati V, Caliaro F, Speca S, Corsetti G, Cardile A, Nisoli E, et al. Essential amino acids improve insulin activation via AKT/mTOR signalling in soleus muscle of aged rats. Int J Immunopathol Pharmacol. 2010; 23: 81-89.
19. Hennige AM, Stefan N, Kapp K, Lehmann R, Weigert C, Beck A, et al. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J. 2006; 20: E381 - E389.
20. Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G, et al. Akt mediates the cross-talk between β -adrenergic and insulin receptors in neonatal cardiomiocytes. Circ Res. 2005; 96: 180-188.
21. White M. Insulin signalling in health and disease. Science. 2003; 302: 1710-1711.
22. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002; 4: 658-665.
23. Von Manteuffel SR, Gingras AC, Ming XF, Sonenberg N, Thomas G. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci USA. 1996; 93: 4076-4080.
24. Marfella R, D'Amico M, Di Filippo C, Siniscalchi M, Sasso FC, Ferraraccio F, et al. The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol. 2007; 6: 35.
25. Ma X, Zhu S. Metabolic syndrome in the prevention of cardiovascular diseases and diabetes - Still amatter of debate? Eur J Clin Nutr. 2013; 67: 518-521.
26. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001; 38(3 Pt 2): 581-587.
27. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin Sci (Lond). 2007; 112: 375-384.
28. Taddei S, Virdis A, Ghiadoni L, Versari D, Salvetti G, Magagna A, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension. 2003; 41: 950-955.
29. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M, Cacchio M, et al. Oxygen-free radical decrease in hypertensive patients treated with lercanidipine. Int Angiol. 2001; 20: 136-140.
30. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens. 2008; 26: 494-500.
31. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med. 1996; 101: 71S - 82S.
32. ONTARGET Investigators, ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med. 2008; 358: 1547-1559.
33. Telmisartan Randomised Assessme Nt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: Arandomised controlled trial. Lancet. 2008; 372: 1174-1183.
34. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al.; Second Australian National Blood Pressure Study Group. Acomparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583-592.
35. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med. 2008; 359: 2417-2428.